Assembling the evidence…
BACKGROUND: Hereditary angioedema (HAE) is associated with a substantial disease burden. Lanadelumab reduced the HAE attack rate during 132 weeks of follow-up in the HELP open-label extension (OLE) Study (NCT02741596). OBJECTIVE: To measure the impact of long-term lanadelumab treatment on patient-reported outcomes (PROs). METHODS: Rollover patients (completed the 26-week HELP study [NCT02586805]) and nonrollovers (newly enrolled) received lanadelumab 300 mg every 2 weeks. PROs (Angioedema Quality of Life Questionnaire [AE-QoL], Short Form Health Survey 12-item version 2, Hospital Anxiety and Depression Scale, Work Productivity and Activity Impairment-General Health Questionnaire, and EQ-5D-5L questionnaire) were assessed at baseline (day 0 of HELP OLE) and various time points until the end-of-study visit. The Angioedema Control Test, Treatment Satisfaction Questionnaire for Medication, and Global Impression of Treatment Response were administered starting at week 52. RESULTS: The mean (SD) change in AE-QoL total score from baseline to end-of-study for rollovers (n = 90) was -10.2 (17.9), exhibiting further improvement from HELP in health-related quality of life (HRQoL); 48.9% of rollovers achieved the previously defined 6-point minimal clinically important difference. Nonrollovers (n = 81) reported a change of -19.5 (21.3). Controlled disease (Angioedema Control Test total score ≥10) was reported by 90.2% of rollovers and 95.9% of nonrollovers at the end of the study. Excellent treatment response was reported by 78.7% of patients and 82.4% of investigators. Results from other PROs indicated a slight improvement in anxiety, a high level of satisfaction with treatment, and increased work productivityor activity. CONCLUSION: Clinically meaningful improvement in HRQoL was exhibited with long-term lanadelumab treatment, supporting the benefit of lanadelumab therapy associated with attack prevention. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02586805 (HELP Study) and NCT02741596 (HELP open-label extension).
Clinically meaningful improvement in HRQoL was exhibited with long-term lanadelumab treatment, supporting the benefit of lanadelumab therapy associated with attack prevention.
treatment-benefit attribution exceeds what a single-arm, open-label extension can identify
The mean (SD) change in AE-QoL total score from baseline to end-of-study for rollovers (n = 90) was -10.2 (17.9); 48.9% of rollovers achieved the previously defined 6-point minimal clinically important difference.
descriptive change is reported, but the overall gain was concentrated in prior-placebo rollovers
Nonrollovers (n = 81) reported a change of -19.5 (21.3).
the reported within-group AE-QoL change is consistent across the abstract, results, and Table 2
Controlled disease (Angioedema Control Test total score ≥10) was reported by 90.2% of rollovers and 95.9% of nonrollovers at the end of the study.
direct end-of-study proportions support the descriptive claim, although AECT lacked a baseline assessment
Excellent treatment response was reported by 78.7% of patients and 82.4% of investigators.
the end-of-study ratings are directly reported, though open-label assessment permits expectation effects
Derived from the full evaluation — not a separate score.
Strengths
The OLE follows patients for up to 132 weeks and reports approximately 162 weeks of cumulative exposure for rollovers, extending the shorter parent-trial PRO evidence.
↳ Methods, Study Design and Patients; Results, AE-QoL; Discussion, p.107
AE-QoL and AECT are disease-specific instruments, and the AE-QoL analysis uses a published 6-point MCID to interpret individual change.
↳ Methods, Patient-Reported Outcomes; Table 1; Results, AE-QoL
The study connects long-term PRO findings to the randomized HELP trial, the prior OLE attack-rate report, international guidance, and other prophylaxis extension studies.
↳ Introduction; Discussion; references 5, 8, 9, 11, and 24–26
Limitations
All participants received open-label lanadelumab, with no analytical strategy addressing expectation effects, regression to the mean, natural history, or other time-varying influences.
↳ Methods, Study Design and Patients and Analysis
The conclusion states that lanadelumab provided sustained improvement and supports treatment benefits, although the design establishes longitudinal change during treatment rather than an isolated causal effect.
↳ Abstract, Conclusion; Conclusions, p.107
The limitations discussion addresses prior prophylaxis, ceiling effects, and early discontinuers but does not explain how the absent comparator restricts causal interpretation.
↳ Discussion, limitations paragraphs, p.107
Table 2 shows a −21.8 AE-QoL change in prior-placebo rollovers versus changes of −2.7 to −5.7 in prior-lanadelumab groups, complicating the overall “further improvement” framing.
↳ Results, AE-QoL; Table 2
The paper adds long-duration, disease-specific PRO data to the HELP program and reports coherent results across the abstract, tables, and figures. The descriptive methodology is strengthened by validated instruments, an AE-QoL MCID, separate cohort reporting, and EOS assessments that included early discontinuers where possible. However, all OLE participants received open-label treatment, and no analysis separates treatment-attributable change from regression to the mean, expectation effects, or time trends. That limitation is not foregrounded in the limitations section, while the abstract and conclusion state that treatment provided improvement and supports therapeutic benefit.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.7
Confidence highThe paper adds up to approximately three years of PRO follow-up and several longitudinal disease-control and treatment-satisfaction measures to the HELP evidence base. This is a meaningful but incremental extension of prior randomized and OLE publications.
This is the longest follow-up of patients in a published study of LTP for HAE.
Validated PRO instruments, an AE-QoL MCID, defined assessment times, separate cohorts, and EOS assessment of early discontinuers support descriptive trajectory reporting. The single-arm, open-label design provides no strategy for separating treatment effects from expectation, time trends, regression to the mean, or selection.
Missing assessments were not imputed.
The paper is structured clearly and reports cohort-specific values with interpretable scale directions. Its conclusion that treatment “provided” improvement and supports therapeutic benefits communicates stronger attribution than the uncontrolled design identifies.
long-term treatment with lanadelumab provided sustained clinically meaningful improvement in HRQoL
The discussion connects the findings to the HELP trial, competing prophylaxis extensions, guidelines, and instrument-specific limitations. It does not identify the absence of a concurrent OLE comparator as a limitation on the causal interpretation used in the conclusion.
These findings support the benefits of lanadelumab therapy associated with attack prevention.
Lower confidence on Positioning — domain match limited.
Caveats4 of 4 checks
Reported PRO values are internally consistent, but the treatment-benefit framing is stronger than the uncontrolled extension design supports. The qualification is particularly material because further AE-QoL improvement among rollovers was concentrated in patients previously assigned placebo.
Ethics approval, informed consent, trial registration, sponsor involvement, author conflicts, and a participant-data access process are disclosed. No supplied-text evidence indicates a research-conduct concern.
Flags: 4 declared / 5 total
22 of 26 checkable references verified
26 references in manuscript
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Lanadelumab is an approved prophylaxis, and the extension supplies long-duration information that can inform treatment discussions. The formal, uncontrolled extension setting limits its use as comparative or real-world implementation evidence.
All patients received up to 132 weeks of treatment
AI-generated, human-governed. Something look off? Contact us to request a review.